Referanslar

1. Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med. 1974;139(6):1369-81. [Crossref]  [PubMed]  [PMC]
2. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature. 1984 Nov 29-Dec 5;312(5993):458-62. [Crossref]  [PubMed]
3. Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol. 2022;18(8):448-63. [Crossref]  [PubMed]  [PMC]
4. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019;50(4):778-95. [Crossref]  [PubMed]  [PMC]
5. Rivers-Auty J, Daniels MJD, Colliver I, Robertson DL, Brough D. Redefining the ancestral origins of the interleukin-1 superfamily. Nat Commun. 2018;9(1):1156. [Crossref]  [PubMed]  [PMC]
6. Dayer J, de Rochemonteix B, Burrus B, Demczuk S, Dinarello CA. Human Recombinant Interleukin I Stimulates Collagenase and Prostaglandin E2 Production by Human Synovial Cells. J Clin Invest. 1986;77:645-8. [Crossref]  [PubMed]  [PMC]
7. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8(9):942-9. [Crossref]  [PubMed]
8. Shi L, Song L, Maurer K, Dou Y, Patel VR, Su C, et al. IL-1 Transcriptional Responses to Lipopolysaccharides Are Regulated by a Complex of RNA Binding Proteins. J Immunol. 2020;204(5):1334-44. [Crossref]  [PubMed]  [PMC]
9. Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49-77. [Crossref]  [PubMed]
10. Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113-4. [Crossref]  [PubMed]
11. Li S, Deng P, Wang M, Liu X, Jiang M, Jiang B, et al. IL-1α and IL-1β promote NOD2-induced immune responses by enhancing MAPK signaling. Lab Invest. 2019;99(9):1321-34. [Crossref]  [PubMed]
12. Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, et al. The Interleukin-1alpha Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines. Front Immunol. 2013;4:391. [Crossref]  [PubMed]  [PMC]
13. Malik A, Kanneganti TD. Function and regulation of IL-1alpha in inflammatory diseases and cancer. Immunol Rev. 2018;281(1):124-37. [Crossref]  [PubMed]  [PMC]
14. Arend WP, Malyak M, Guthridge CJ, Gabay C. INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology. Annu Rev Immunol 1998;16:27-55. [Crossref]  [PubMed]
15. Arnold DD, Yalamanoglu A, Boyman O. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. Front Immunol. 2022;13:888392. [Crossref]  [PubMed]  [PMC]
16. Kinch MS. An overview of FDA-approved biologics medicines. Drug Discov Today. 2015;20(4):393-8. [Crossref]  [PubMed]
17. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443-52. [Crossref]  [PubMed]
18. Lachmann HJ, Kone-Paut I, M.D., Kuemmerle-Deschner JB, Leslie KS, Hachulla E, et al. Use of Canakinumab in the CryopyrinAssociated Periodic Syndrome. The New England Journal of Medicine. 2009;360(23):2416-25. [Crossref]  [PubMed]
19. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. [Crossref]  [PubMed]
20. Rider P, Carmi Y, Cohen I. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol. 2016;2016:9259646. [Crossref]  [PubMed]  [PMC]
21. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20(3):102763. [Crossref]  [PubMed]
22. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs. 2011;3(1):49-60. [Crossref]  [PubMed]  [PMC]
23. Vinit C, Georgin-Lavialle S, Theodoropoulou A, Barbier C, Belot A, Mejbri M, et al. Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review. Front Immunol. 2021;12:744780. [Crossref]  [PubMed]  [PMC]
24. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. PHARMACOKINETICS, SAFETY AND IMMUNOMODULATORY EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN HEALTHY HUMANS. Cytokine. 1992;4(5):353-60. [Crossref]  [PubMed]
25. Fields JK, Gunther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. Front Immunol. 2019;10:1412. [Crossref]  [PubMed]  [PMC]
26. Wiken M, Hallen B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. Clin Rheumatol. 2018;37(12):3381-6. [Crossref]  [PubMed]
27. Rodriguez-Smith J, Lin YC, Tsai WL, Kim H, Montealegre-Sanchez G, Chapelle D, et al. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis Rheumatol. 2017;69(6):1325-36. [Crossref]  [PubMed]  [PMC]
28. Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146(5):925-37. [Crossref]  [PubMed]  [PMC]
29. Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71(7):1163-73. [Crossref]  [PubMed]  [PMC]
30. Fisher CJ, Dhainaut JA, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome Results From a Randomized, Double-blind, Placebo-Controlled Trial. JAMA. 1994;271(23):1836-43. [Crossref]  [PubMed]
31. Anakinra. US Food and Drug Administration (FDA) approved product information. Revised December 2020. US FDA. (Available online at (Accessed September 15, 2023) [Link]
32. Anakinra. European Medicines Agency (EMA) Summary of product characteristics. Last updated December 22, 2021. European Medicines Agency. (Available online at (Accessed September 15, 2023) [Link]
33. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-12. [Crossref]  [PubMed]
34. Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, Pilstrom B. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012;32(2):295-9. [Crossref]  [PubMed]  [PMC]
35. Canna S, Frankovich J, Higgins G, Narkewicz MR, Nash SR, Hollister JR, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J. 2009;7:21. [Crossref]  [PubMed]  [PMC]
36. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67. [Crossref]  [PubMed]  [PMC]
37. Sun H, Van LM, Floch D, Jiang X, Klein UR, Abrams K, Sunkara G. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. J Clin Pharmacol. 2016;56(12):1516-27. [Crossref]  [PubMed]
38. Canakinumab. US Food and Drug Administration (FDA) approved product information. Revised August 2023. US FDA. (Available online at (Accessed September 15, 2023) [Link]
39. Canakinumab. European Medicines Agency (EMA) Summary of product characteristics. Last updated August 2023. EMA. (Available online at (Accessed September 15, 2023) [Link]
40. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908-19. [Crossref]  [PubMed]
41. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9(1):47-52. [Crossref]  [PubMed]
42. M.F. M. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc). 2009;45(6):423-30. [Crossref]  [PubMed]
43. Rilonacept. US Food and Drug Administration approved product information. Revised 03/2021. (Accessed on September 15, 2023) [Link]
44. Rilonacept. European Medicines Agency (EMA) Summary of product characteristics. Last updated September 24, 2012. European Medicines Agency. (Available online at (Accessed September 15, 2023) [Link]
45. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(9):2570-9. [Crossref]  [PubMed]  [PMC]
46. Sag E, Akal F, Atalay E, Akca UK, Demir S, Demirel D, et al. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford). 2020;59(11):3324-9. [Crossref]  [PubMed]
47. Ozen S, Kone-Paut I, Gul A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47(1):115-20. [Crossref]  [PubMed]
48. Ozen S, Sag E, Ben-Chetrit E, Gattorno M, Gul A, Hashkes PJ, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford). 2021;60(8):3799-808. [Crossref]  [PubMed]
49. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516-8. [Crossref]  [PubMed]
50. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008;75(4):504-5. [Crossref]  [PubMed]
51. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017;69(4):854-62. [Crossref]  [PubMed]
52. Ozen S, Ben-Cherit E, Foeldvari I, Amarilyo G, Ozdogan H, Vanderschueren S, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020;79(10):1362-9. [Crossref]  [PubMed]  [PMC]
53. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever. Annals of Internal Medicine. 2012;157:533-41. [Crossref]  [PubMed]
54. Sener S, Cam V, Batu ED, Kasap Cuceoglu M, Balik Z, Aliyev E, et al. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever. Rheumatology (Oxford). 2023;62(11):3700-5. [Crossref]  [PubMed]  [PMC]
55. ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636-44. [Crossref]  [PubMed]
56. Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64. [Crossref]  [PubMed]  [PMC]
57. Walker UA, Tilson HH, Hawkins PN, Poll TV, Noviello S, Levy J, et al. CACZ885D2401 Study Investigators. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open. 2021;7(2):e001663. [Crossref]  [PubMed]  [PMC]
58. Welzel T, Kuemmerle-Deschner JB. Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today? J Clin Med. 2021;10(1):128. [Crossref]  [PubMed]  [PMC]
59. Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weissbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016;55(4):689-96. [Crossref]  [PubMed]
60. Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, et al. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford). 2014;53(4):665-70. [Crossref]  [PubMed]
61. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70(12):2155-8. [Crossref]  [PubMed]
62. Kostjukovits S, Kalliokoski L, Antila K, Korppi M. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr. 2015;174(6):707-14. [Crossref]  [PubMed]
63. Ozen S, Kuemmerle-Deschner JB, Cimaz R, Livneh A, Quartier P, Kone-Paut I, et al. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2017;69(4):578-86. [Crossref]  [PubMed]
64. Delaleu J, Deshayes S, Rodrigues F, Savey L, Riviere E, Silva NM, et al. Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford). 2021;60(12):5775-84. [Crossref]  [PubMed]
65. Grimwood C, Despert V, Jeru I, Hentgen V. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford). 2015;54(9):1749-51. [Crossref]  [PubMed]
66. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58(5):1516-20. [Crossref]  [PubMed]
67. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747-54. [Crossref]  [PubMed]  [PMC]
68. De Matteis A, Bracaglia C, Pires Marafon D, Piscitelli AL, Alessio M, Naddei R, et al. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology (Oxford). 2022;61(4):1621-9. [Crossref]  [PubMed]
69. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486-96. [Crossref]  [PubMed]
70. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021;384(1):31-41. [Crossref]  [PubMed]
71. Kuemmerle-Deschner JB, Welzel T, Hoertnagel K, Tsiflikas I, Hospach A, Liu X, et al. New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Rheumatology (Oxford). 2020;59(11):3259-63. [Crossref]  [PubMed]
72. Garg M, de Jesus AA, Chapelle D, Dancey P, Herzog R, Rivas-Chacon R, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017;2(16):e94838. [Crossref]  [PubMed]  [PMC]
73. Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatric Rheumatology. 2014;12:1-5. [Crossref]  [PubMed]  [PMC]
74. Kone-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, et al. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease. Arthritis Rheumatol. 2021;73(1):151-61. [Crossref]  [PubMed]
75. Batu ED, Sener S, Cam V, Aktay Ayaz N, Ozen S. Treatment with Biologic Drugs in Pediatric Behcet's Disease: A Comprehensive Analysis of the Published Data. BioDrugs. 2023;37(6):813-28. [Crossref]  [PubMed]
76. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol. 2015;34(7):1293-301. [Crossref]  [PubMed]
77. Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, et al. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behcet's Disease. Ocul Immunol Inflamm. 2020;28(2):298-304. [Crossref]  [PubMed]
78. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-46. [Crossref]  [PubMed]  [PMC]
79. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022;74(4):e1-e20. [Crossref]  [PubMed]  [PMC]
80. Basaran O, Batu ED, Kaya Akca U, Atalay E, Kasap Cuceoglu M, Sener S, et al. The Effect of Biologics in the Treatment of Multisystem Inflammatory Syndrome in Children (Mis-C): A Single-Center Propensity-Score-Matched Study. Children (Basel). 2023;10(6):145. [Crossref]  [PubMed]  [PMC]
81. Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023;82(10):1271-85. [Crossref]  [PubMed]  [PMC]
82. Sonmez HE, Demir S, Bilginer Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329-35. [Crossref]  [PubMed]
83. Sözeri B, Demir F, Barut K, Atalay E, Kisaarslan P, Özdel S, et al. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study. Clinical and Experimental Rheumatology. 2023. [Crossref]
84. Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. Arthritis Rheumatol. 2022;74(7):1102-21. [Crossref]  [PubMed]  [PMC]